ASTS · Investment summary · as of 12 August 2026
Priced for an operating path the record does not support
Business type: Capital scale-up · venture-like, not yet economically observable
The evidence needed to judge business quality is not established, so the underwriting supports no position.
At $74.31, ASTS requires a 147% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 64%.
The only disagreement with the market this security can express is whether SpaceMobile Service revenue appears at extraordinary scale and speed.
Street revenue is $164m for the current year, $672m the year after. Estimates have moved down on both lines. A bridge requires both sides to be valuing the same thing on a comparable instrument.
The disagreement is scheduled to resolve inside Q4 2026 - H1 2027, when the dated events below land.
The strongest argument against this view: a financing gap arriving when the equity cannot absorb it.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The only disagreement with the market this security can express is whether SpaceMobile Service revenue appears at extraordinary scale and speed. |
| What do we forecast? | Revenue growth of 64% demonstrated. |
| What does Street forecast? | Consensus: current-year revenue $164m; next-year revenue $672m; current-year earnings per share -$1.49. Down on both lines. |
| Where do we differ? | A bridge requires both sides to be valuing the same thing on a comparable instrument. On revenue growth, the difference between what the price requires and what the business has demonstrated is -82.9 percentage points. |
| What is it worth? | Outcome values run from $3.00 to $183.02 per share. The spread is the thesis: this is a distribution of outcomes, not a point estimate. |
| Why now? | Q4 2026 - H1 2027: beta service initiation (promised in 2026), Q3 2026 results (~November 2026), the J-LEO/Rakuten final award, the Ligado Chapter 11 closing, and the BB14-16 / BB17-46 launch cadence. |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| 30 June 2027 | The constellation-cadence leg of the thesis | At least 25 BlueBird satellites in orbit by 30 June 2027 | Fewer than 25 BlueBird satellites in orbit by 30 June 2027 |
| FY2026 10-K (~March 2027) | The near-term commercial-execution leg | FY2026 revenue at or above $150.0m | FY2026 revenue below $150.0m |
| each raise; each 10-Q | The financing-access leg — the impairment case's named cause | A capital raise executed at no more than a 25% discount to the prevailing price, and quarter-end cash plus restricted… | A capital raise executed at more than a 25% discount to the prevailing price, OR quarter-end cash plus restricted cash… |
| quarterly through Q2 2027 | The commercialisation leg — the entire terminal value | Revenue is recognised on the line the thesis depends on | No revenue recognised from the SpaceMobile Service in any period through the quarter ending 30 June 2027 |
A financing gap arriving when the equity cannot absorb it. The mechanism is specific and it is not a multiple compressing — a launch or integration setback (BB7 is the demonstrated instance: placed into a lower-than-planned orbit by the New Glenn 3 upper stage on 19 April 2026 and de-orbited, a $125.911m loss on involuntary conversion net of $21.595m of insurance recovery) pushes continuous commercial service beyond the funded constellation, at a cash consumption rate of roughly $820m per quarter of capex plus opex; a rescue raise then prices at a deep discount to a depressed equity, or the Ligado transaction fails to close and the L-band spectrum position unwinds. This removes the asset's optionality at a named counterparty through a named mechanism; it does not re-run the same model at a lower multiple.
Estimated probability 22%, against the 13% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
Any position is an optionality-sleeve holding sized by the sleeve's own budget, not by E[R] rank — State D names are excluded from the ranked book, so there is no rank to size from. Trim back to the sleeve cap whenever appreciation doubles the position's weight.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not determined | Is the business worth owning under its declared economic type? Not established on the evidence on file. |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | $1,010m of 20-day average dollar volume. Liquidity is not a constraint at any size this book would take. |
| Downside | Met | A financing gap arriving when the equity cannot absorb it. |
| Momentum | Met | Timing only; blocks nothing. 12-1 momentum +49.9% against SPY +21.2% — a strong cross-sectional reading. |
| Catalyst | Met | Q4 2026 - H1 2027: beta service initiation (promised in 2026), Q3 2026 results (~November 2026), the J-LEO/Rakuten final award, the Ligado Chapter 11 closing, and the BB14-16 / BB17-46 launch cadence. |
| Consensus | Not determined | A bridge requires both sides to be valuing the same thing on a comparable instrument. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -82.9 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is whether this is a business worth owning at all — the evidence for its quality is not established. The next evidence that should change the portfolio decision is the test dated 30 June 2027, or a daily close below $57.02, which forces an immediate review.